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Available online 25 June 2016Idiopathic normal pressure hydrocephalus (iNPH) is a late-onset surgically alleviated, progressive disease. We
characterize a potential familial subgroup of iNPH in a nation-wide Finnish cohort of 375 shunt-operated
iNPH-patients. The patients were questionnaired and phone-interviewed, whether they have relatives with ei-
ther diagnosed iNPH or disease-related symptomatology. Then pedigrees of all families with more than one
iNPH-case were drawn. Eighteen patients (4.8%) from 12 separate pedigrees had at least one shunt-operated rel-
ative whereas 42 patients (11%) had relativeswith two ormore triad symptoms. According to multivariate logis-
tic regression analysis, familial iNPH-patients had up to 3-fold risk of clinical dementia compared to sporadic
iNPH patients. This risk was independent from diagnosed Alzheimer's disease and APOE ε4 genotype.
This study describes a familial entity of iNPH offering a novel approach to discover the potential genetic charac-
teristics of iNPH. Discovered pedigrees offer an intriguing opportunity to conduct longitudinal studies targeting
potential preclinical signs of iNPH.



















n@kuh.fi (V. Leinonen).1. Introduction
Idiopathic normal pressure hydrocephalus (iNPH) is a late-onset
progressive brain disease with disturbance in cerebrospinal fluid (CSF)
dynamics. Clinical characteristics include a triad of deteriorated gait, uri-
nary incontinence and cognitive impairment, together with enlarged
brain ventricles [1–3]. Symptoms can be alleviated with a CSF shunt,
but the long term impact seems modest only [3–6].
The reported annual incidence of iNPH varies from 0.5/100,000 to
5.5/100,000. The estimated prevalence is 22/100,000 increasing with
age and in the elderly populations it varies from 0.5% up to 5.9% [7–10].
12 J. Huovinen et al. / Journal of the Neurological Sciences 368 (2016) 11–18The pathophysiological basis of iNPH remains elusive [1,11].
Alzheimer's disease (AD)-related neuropathological findings and vascu-
lar lesions are common, and concomitant AD may hamper the initial
benefit from a shunt [4,5,12]. Shunting and iNPH itself may influence
the CSF dynamics of amyloid-β (Aβ) clearance [13–15].
Portenoy et al. in 1984were the first to present iNPH as a potentially
inherited disease.
[16]. A total of 8 iNPH-families, reported previously suggest a famil-
ial subgroup of iNPH with potential autosomal dominant inheritance
(Table 1[16–22]) including a family with essential tremor and concom-
itant iNPH (ETINPH) with linkage to 19q12–13.31 [15,16]. Still, little is
known about the familial characteristics of iNPH.
We first analyzed the overall incidence of shunt-operated iNPH in
the Finnish population, and then identified potential iNPH families by
disease history in the pedigrees.
2. Methods
2.1. Data collection and selection of patients
In Finland, all surgical procedures on CSF disorders are carried out in
six neurosurgical units, with a defined catchment population (Supple-
mentary Table 1). The patient registries of the six units were retrospec-
tively screened to identify all patients shunted due to NPH. Potential
patients were searched based on both operative procedure codes and
diagnostic code (ICD 10; G91.2). Patient records were reviewed by a
neurosurgeon to exclude any potential secondary etiology including ob-
structive hydrocephalus. Overall 1095 patients with possible or proba-
ble iNPH [3] were included in the study (Supplementary Fig. 1). The
patients were shunted between 1993 and 2014 the timeframe varying
between neurosurgical units (Supplementary Table 1, Supplementary
Fig. 1).
Patients were sent an informed consent with 6-page questionnaire
containing patient information form (including smoking, use of alcohol,
physical performance, chronic and previous diseases, current medica-
tion, surgeries performed) and iNPH-item (shunt and shunt response,
other diagnosed neurodegenerative diseases, medication for memory
disease, iNPH-symptoms and family anamnesis with contact informa-
tion of relativeswilling to participate in the study). Altogether 616 ques-
tionnaires (56%) fulfilled by the patient or next of kin were returned.
All questionnaire data from patients with informed consent and ad-
equately filled form (n= 469; 42.9%) was screened by a neurosurgeon
to further confirm the exclusion of any potential secondary etiology ofTable 1
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were subarachnoid hemorrhage (SAH), intracerebral hemorrhage,
meningitis or craniotomyprior to shunt surgery aswell as aqueduct ste-
nosis or another obstruction potentially affectingCSF-dynamics. Unwill-
ingness to participate in genealogy or offer family data was an
additional exclusion criterion. Based on this, 94 patients were excluded
from further analysis limiting the final number of patients to 375 (34%
of the original sample of 1095) with probable iNPH [3].
Patients with reported familial iNPH-symptomatology (n = 60)
were approached in terms of phone interviews. The aims of each inter-
view were to exclude other disorders causing the triad symptoms and
confirm the information reported on the questionnaire. Furthermore,
all available healthy relatives and relatives with triad symptoms
(Table S1) were first contacted by the proband. After that, the relatives
were sent an informed consent and identical questionnaire (150 out
204 returned, 74% response rate) in order to validate the information,
to define their interest in participating in the study and give a blood
sample for genetic study. The relatives reporting possible iNPH related
symptoms were also phone interviewed.
Relying on the data gathered from the questionnaire and phone in-
terviews, a pedigree of each iNPH-family was drawn (Fig. 2). The level
of information indicating familial iNPHwas divided into two categories:
1) probable familial iNPH (at least one relative with shunt due to iNPH),
and 2) possible familial iNPH (at least one relativewith ≥2 self-reported
triad symptoms) [3,23]. Patients fulfilling neither of the two categories
were grouped as sporadic iNPH.
2.2. Geographical analysis
For geographical evaluation, iNPH patients shunted from 2010 until
2012 (comparable data available from all participating units, n = 144
out of 375) were categorized by home county. For yearly incidence, a
mean number of shunt-operated iNPH patients collected during three
consecutive years was divided by a mean number of population aged
higher than 60 years during the corresponding time framewith regional
presentation (Fig. 1A). Additionally, the birth municipalities of familial
(n = 54, Fig. 1B) and sporadic (n = 268, Fig. 1C) patients were graphi-
cally examined.
2.3. APOE-genotyping
Genomic DNA was extracted from venous blood samples using
QIAamp DNA blood mini extraction kit (QIAGEN). APOE genotypingormation
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ws. Moreover, symptomatic essential tremor affected all of these patients and 11
s.
had clinically documented features with ventriculomegaly. In addition four other
rs with interview-based symptomatology were discovered.
ed together their entire lives being exposed to similar environmental factors. They
d clinical iNPH with a favorable post-shunt outcome.
of 20 shunted patients and 21 controls was mapped. Questionnaire data of 291
latives from 41 families was collected and compared in a case-control setting. 7% of
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r-old sisters both with early-onset symptomatology and beneficial response to shunt.
8-year-old daughters are both suffering from urinary incontinence of unknown
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Fig. 1.A) Regional distribution of 144 iNPH patients shunted between 2010 and 2012. The three yearsmean number of shunted patients was divided by themean of local population aged
over 60 during the corresponding years. Presented asmean incidence per 100,000 inhabitants. B) Birth municipalities of 54 familial iNPH-patients. C) Birth municipalities of 268 sporadic
iNPH-patients.
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ing assays (Applied Biosystems (ABI), Foster City, CA, USA) for two sin-
gle-nucleotide polymorphisms (rs429358 and rs7412) and an allelic
discrimination method on the ABI 7000 platform [24]. All the relatives
participating in the study were sent blood vials and information letter
via mail. Blood samples were collected at local health centers. Overall
APOE was genotyped from 357 shunted patients (95%) and 150
relatives.2.4. Statistical analyses
Only shunt operated iNPH patients (n = 375) were included into
the statistical analyses. The variables were compared between famil-
ial and sporadic groups by performing Chi-square test for categorical
variables and Student's t-test (normally distributed) or non-para-
metric Mann-Whitney U test (non-normally distributed) for contin-
uous variables. Multivariate logistic regression analysis was
performed to account for confounding by other clinical variables in
the analysis of differences between familial and sporadic iNPH-pa-
tients. All the variables analyzed were based on the questionnaire
data except the APOE-analyses and in-depth characterization in
Table 3. To avoid bias, symptomatic relatives were excluded from
the analyses and family anamnesis was only used for grouping
shunt-operated iNPH-patients. Variables were analyzed between
three groups: 1) “Sporadic iNPH” (n = 315, shunt-operated iNPH-
patients with no self-reported familial symptomatology), 2) “Possi-
ble familial iNPH” (n = 60, shunt-operated iNPH-patients with at
least one relative with ≥2 self-reported triad symptoms) and 3)
“Probable familial iNPH” (n= 18 out of 60 possible familial iNPH pa-
tients, shunt operated iNPH-patients with at least one diagnosed
iNPH-relative). The standard p = 0.05 was considered to be the
threshold value of statistical significance. SPSS statistical software
(version 22.0, SPSS Inc., Chicago, Illinois) was used in the analyses.2.5. Ethical issues
The study was approved by the Kuopio University Hospital (KUH)
Research Ethics Committee. All patients and their relatives included in
the study gave an informed consent.3. Results
The age-adjusted yearly incidence of shunt-operated iNPH varied
from0 to 26 cases per 100,000 inhabitants agedover 60 andwas highest
in Eastern Finland (Fig. 1A).
Altogether 60 patients (16% out of 375) had a possible or probable
familial iNPH; 18 (4.8%) had probable (shunted) iNPH relative and 42
possible iNPH-relative (Table 2). Gender distribution was equal in fa-
milial and sporadic groups. The familial group was three years older at
shunting (p = 0.008). No statistical difference was found in alcohol
usage or smokingbetween the groups. No significant differencewasdis-
covered in the frequency of APOE ε4 allele between familial and sporadic
iNPH and controls. The self-reported benefit (for any of the iNPH-relat-
ed symptoms) for shunt-surgery was reported 100% among patients
with probable familial iNPH, 90.9% among patients with possible famil-
ial iNPH and 92.1% in sporadic group (p = 0.788, Table 2).
Overall 12 shunted and 42 possible iNPH pedigrees were discovered
(Tables 2 & 3). Shunted relatives were mainly first-degree [15/19 sib-
lings (9 sisters, 6 brothers; one patient had two shunted siblings), a fa-
ther, a son and an uncle] as well as other symptomatic relatives [30/59
(51%) siblings (16 sisters, 14 brothers) 24/59 (41%) parents (17
mothers, 7 fathers), a daughter, a cousin, two aunts and an uncle].
Twelve shunted relatives were also index patients.
Clinical characteristics of 12 pedigrees with at least two shunted pa-
tients were further examined by utilizing available registries (Table 3).
Six out of 19 relatives had APOE ε4 allele. All familial iNPH patients
with available questionnaire or registry data were shunt responsive.
Table 2
Comparison of questionnaire data by familial symptomatology in patients with diagnosed iNPH (n = 375).
A) Sporadic iNPH (n = 315)
B) Possible familial iNPH (n =
60)






Age at shunt (mean and SD) 70.3 (±7.7) 73.2 (±6.6) 74.06 (±6.68) 0.008a 0.046a
Shunt response (self reported) 267/290 (92.1%) 50/55 (90.9%) 17/17 (100%) 0.788 0.381
Follow-up time (from shunt until the
questionnaire)
4.2 (±3.9) 3.4 (±2.6) 3.6 (±2.3) 0.243b 0.921b
Sex (F/M) 170/145 32/28 7/11 1.000c 0.233
BMI (mean and SD) 28.6 (±4.8) 28.2(±5.3) 27.7 (±5.7) 0.518a 0.502a
Smoking
-Smoker 15/312 (4.8%) 2 (3.3%) 0 0.431c 0.626
-Ex-smoker 79/312 (25.3%) 11 (18.3%) 4/18 (22.2%)
Consumes alcohol 109/313 (34.8%) 17 (28.3%) 7/18 (38.9%) 0.373c 0.801
Complete triad 118 (37.5%) 32 (53.3%) 7/18 (38.9%) 0.030c 1.000
Prevalence of APOE ε4 87/298 (29.2%) 15/59 (25.4%) 6/17 (35.3%) 0.637c 0.786
Memory and neurological comorbidities
-Diagnosed AD 43/295 (14.6%, 51.2% APOE
ε4)
13/60 (21.7%, 33.3% APOE ε4) 3/18 (16.7%) 0.176c 1.000c
-Other diagnosed neurodegenerative disorder 23/281 (8.2%) 6/59 (10.2%) 4/18 (22.2%) 799c 0.067c
-Clinical dementia 56 (17.8%) 22 (36.7%) 7/48 (38.9%) 0.001c 0.035c
-“I am having problems with memory” 186/289 (64.4%) 48/59 (81.4%) 13/18 (72.2%) 0.014c 0.615c
-Memory drug 44/307 (14.3% %) 13/58 (22.4%) 3/18 (16.7%) 0.173c 1.000c
-Epilepsy 18 (5.7%) 4 (6.7%) 2/18 (11.1%) 1.000 0.613c
-Parkinsonism 13 (4.1%) 1 (1.7%) 1/18 (5.6%) 0.485c 1.000c
Cardiovascular comorbidities
-Hypertension 175 (55.6%) 41 (68.3%) 15/18 (83.3%) 0.087c 0.026c
-Coronary disease 62 (19.7%) 9 (15.0%) 2/18 (11.1%) 0.474c 0.542c
-Stroke/TIA 45 (14.3%) 7 (11.7%) 0/18 0.687c 0.147c
-Venous thrombosis 18 (5.7%) 8 (13.3%) 2/18 (11.1%) 0.048c 0.613c
-Diabetes 111 (35.2%) 18 (30.0%) 4/18 (22.2%) 0.463c 0.316c
Other comorbidities
-Rheumatoid arthritis 17 (5.4%) 4 (6.7%) 1/18 (5.6%) 0.758c 1.000c
-Other rheumatoid diseased 13 (4.1%) 8 (13.3%) 1/18 (5.6%) 0.010c 1.000c
-Spinal stenosis 32 (10.2%) 12 (20.0%) 6/18 (31.3%) 0.046c 0.010c
Performance
-Is able to fill the questionnaire independently 156/311 (50.2%) 21/60 (35.0%) 8/18 (44.4%) 0.035c 0.809c
a t-Test.
b Mann-Whitney U test.
c χ2-test.
d These include fibromyalgia (n = 6), polymyalgia rheumatica (n = 4), psoriasis (n = 2) and 9 non-specific cases.
Table 3
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Cortical brain biopsies and validated clinical and follow-up data are available from KUH patients. *Tau indicates hyperphosphorylated tau detected by AT8 antibody. Symptomatic and
cognitive status of other patients relies on questionnaire- and interview-based data. All subjects with any clinical data are clinically confirmed iNPH-patients. With respect to pedigrees
I, III, VII & X the shunt status of relatives has been confirmed bymedical interviews and available patient registry data. *Patient XII-B is included inKuopio NPH-registry but did not respond
to the questionnaire and was not treated as an index patient.
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15J. Huovinen et al. / Journal of the Neurological Sciences 368 (2016) 11–18With respect to symptomatology and cognitive status, the preva-
lence of a complete triad of NPH-related symptoms was more frequent
in familial group (53.3% vs. 37.5%; p=0.03) as well as subjective mem-
ory problems (p=0.014) compared to sporadic iNPH. Clinical dementia
was more common in familial (36.7%) than sporadic patients (17.8%;
p = 0.001). AD was the most frequent specific clinical diagnosis of de-
mentia. Furthermore, spinal stenosis, venous thrombosis and rheuma-
toid diseases were more common in familial group (Table 2).
According to multivariate analysis, only clinical dementia and rheuma-
toidmanifestations remained significantlymore frequent in the familial
than sporadic iNPH (Table 3).
In a subgroup analysis of patients with shunt-operated iNPH-rela-
tive, risk of clinical dementia remained significant even when adjusted
to age, sex APOE ε4 and concomitant AD ([OR] 4.3; 95% CI 1.1–19.2). In-
terestingly, according to multivariate analysis hypertension and spinal
stenosis were the most common in this group (Tables 2 & 4). Rheuma-
toid diseases, venous thrombosis, and prevalence of complete triad did
not reach statistical significance.
The genograms of iNPH-families were sketched from each familial
patient, the most interesting of them displayed in Fig. 2. A number of
shunted iNPH-siblings and even identical twins both with shunt-re-
sponsive iNPH in a year interval were discovered.
In the Kuopio University Hospital (KUH) area, 160 iNPH-patients
were included in our cohort, those of whom twelve (7.5%) had at least
one shunted relative and fourteen (8.8%) at least one possible iNPH-rel-
ative. Themean agewas 76.6 years and only six patients were under 65.
Since λR is the risk of disease in the relative of index patient, divided by
general prevalence that is:
λ ¼ Pr D ARjð Þ
Pr Dð Þ
A rough estimate of λR in KUH-area would be ~200 on all familial
subjects when using the local prevalence of 65+ population. However,
based on the KUH NPH-registry, the overall prevalence is much higher
(data not shown). Still, extrapolation would diminish the portion of fa-
milial iNPH-patients and thus absolute percentage is themost unbiased
estimate. To get an accurate λR, more complete pedigree data and epi-
demiological numbers are required.
4. Discussion
This study is the first to evaluate familial occurrence of iNPH in a na-
tion-wide cohort of shunt-operated iNPH patients. Apart from individu-
al case reports, only McGirr and Cusimano have used a systematic
approach yet comparing the occurrence of iNPH related symptoms in
relatives of iNPH-patients to relatives of non-INPH controls [20].Table 4
Logistic regression analysis comparing possible familial iNPH (n = 60), and probable familial i
Comorbidity Model
Possible familial iNPH (n
OR 95% CI
Dementia Univariate 2.678 1.471–4
Multivariate⁎ 2.693 1.188–6
Hypertension Univariate 1.726 0.959–3
Multivariate⁎⁎ 1.690 0.914–3
Venous thrombosis Univariate 2.483 0.976–6
Multivariate⁎⁎ 2.311 0.900–5
Rheumatoid manifestation Univariate 3.833 1.448–1
Multivariate⁎⁎ 3.599 1.399–9
Spinal stenosis Univariate 2.052 0.956–4
Multivariate⁎⁎ 1.975 0.914–4
Complete triad Univariate 1.908 1.094–3
Multivariate⁎⁎ 1.346 0.704–2
⁎ Multivariate analysis included adjustment to sex, age, other comorbidities, APOE ε4 and d
⁎⁎ With respect to other comorbidities, APOE ε4 and diagnosed ADwere excluded frommultiFurthermore, the current study with a notable number of patients
more likely detects the potential specific characteristics of the familial
iNPH.
Our results confirm a familial entity of iNPH with a notable preva-
lence. Since clinical dementia seems to be more frequent in the familial
group, the proposed familial iNPH may be clinically more aggressive
than the sporadic iNPH. This increased risk of dementia seems to be in-
dependent from clinically diagnosed AD and APOE ε4 genotype raising
further suspicion of iNPH as an independent entity to potentially
cause dementia even when treated with current standards [4].
4.1. Characteristics of familial subgroup
Themost significant finding was the extent to which possible famil-
ial iNPH occurs. Every sixth (16%) of the study patients had at least one
relative with shunt-operated or possible iNPH. The number of patients
with possible iNPH relative (16%) was close to that previously reported
byMcGirr and Cusimano (2/20; 10%) [20]. Nearly all shunted and symp-
tomatic relatives were first-degree. However, the questionnaire and in-
terview-based approach is suboptimal to reach more distant relatives
and thus a major potential source of error. The number of potential
iNPH-pedigrees discovered was surprisingly high (12 shunt-operated,
42 possible) since only 8 separate pedigrees have been described previ-
ously (Table 1).
Comparing the familial group to sporadic, we discovered significant
differences concerning the prevalence of complete triad, memory prob-
lems and clinical dementia referring to potentially more severe symp-
tomatology among familial patients. Clinical dementia was even
highlighted in the subgroup analysis withmultiple adjustments regard-
less of modest sample size. Unexpectedly the mean age at shunting in
the familial patients tended to be higher opposingmost of the other he-
reditary forms of neurodegenerative diseases manifesting usually earli-
er than sporadic forms. Unfortunately, we were not able to define the
exact onset-age when the first clinical symptoms appeared. Further-
more, patients with positive family historymight have beenmore likely
interested in participating in the study. Despite more frequently report-
ed clinically diagnosed dementia in the familial group, differences in
functional capacity and residency were relatively minor.
4.2. Potential sources of error
The main sources of potential error were mainly questionnaire-
based data and the decreased cognitive performance in a large number
of patients. Only 47% of the patients could fill the entire form indepen-
dently thus in half of the patients the information was given by next
of kin. Furthermore, we believe that the patients with the lowest capac-
ity weremore often unable to return the questionnaire and the patients
with iNPH or iNPH related symptoms in the familymay have beenmoreNPH (n= 18 out of 60) with sporadic iNPH (n = 315) as a reference.
= 60) Probable familial iNPH (n = 18 out of 60)
p OR 95% CI p
.875 0.001 2.943 1.093–7.926 0.033
.107 0.018 4.311 1.103–19.224 0.047
.107 0.069 4.000 1.135–14.093 0.031
.127 0.095 4.116 1.125–15.053 0.032
.316 0.056 2.062 0.440–9.669 0.358
.937 0.082 2.230 0.390–12.751 0.367
0.146 0.007 1.367 0.169–11.068 0.770
.676 0.011 1.494 0.140–15.903 0.739
.404 0.065 4.422 1.554–12.585 0.005
.265 0.083 3.416 1.073–10-874 0.038
.327 0.023 1.062 0.401–2.816 0.903
.573 0.369 0.516 0.145–1.835 0.306
iagnosed AD.
variate model due to limited sample size and irrelevant statistical effect (data not shown).
Fig. 2. Eightmultiplex iNPH-pedigrees. Black symbols indicate patientswith shunt/diagnosed iNPH. Potential iNPH/AD-patients are colored gray. Symptoms of theHakim triad aremarked
with G (gait problems), U (urinary incontinence) and M (memory deficit). APOE alleles are included in binumeric formwhen available. Pedigrees A–C present multiple siblings affected.
Additionally, history of impaired memory on mother's side was reported with respect to pedigree A. Pedigree D: identical twins both with diagnosed, shunt-responsive iNPH. The twins
had lived together with similar environmental exposure. E & G: two pedigrees withmultiple affected first-degree relatives and three siblings with probable AD. This finding suggests that
there may be common inherited elements manifesting as various, parallel clinical types of neurodegeneration. APOE ε4 was detected in both of these families. Pedigrees F & H indicate
longitudinal expression of familial iNPH, referring to autosomal (dominant) inheritance.
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sponse rate (92%) for the shunt, especially in those with more than one
shunted patients in the family. Also, we were not able to confirm iNPH
radiologically in the relatives with possible iNPH. Also, low response
rate and strict etiological exclusion criteria presumably leave a number
of potential pedigrees yet to be discovered. In addition, we were not
able to screen the families of the deceased iNPH patients limiting gener-
alizability of our results and warranting further prospective study.
4.3. Comorbidities
The familial iNPH cases were expected to have less co-morbidities.
Venous thrombosis was more common in the familial group yet not inconfirmed pedigrees. Interestingly, hypertension – a common comor-
bidity in patients with iNPH [25] – was even more frequent in familial
cases even after multiple adjustments. Overall, the role of vascular fac-
tors affecting iNPH etiology in general remains unknown. Bateman &
Siddique discovered recently that patients with chronic hydrocephalus
had narrower sinuses with increased venous pressure and weakened
blood flow [26]. On the other hand, perivascular pathways and e.g. crib-
riform lamina have shown to play a role as a potential compensatory or
even primary route for CNS fluid absorption [27].
Regardless of the increased number of reported clinical dementia in
familial iNPH patients, no significant difference was discovered in the
prevalence of clinical AD. This is supported by the multivariate analyses
indicating that the risk of dementia seems to be independent from AD,
17J. Huovinen et al. / Journal of the Neurological Sciences 368 (2016) 11–18APOE ε4, age and sex. However, higher susceptibility to amyloid deposi-
tion in all patients with iNPH is well documented corresponding to our
findings as well. Overall, the prevalence of clinically diagnosed AD in
both the familial and the sporadic group (22% vs. 15%) was relatively
high comparing with the previous epidemiological studies on AD and
considering the mean age of our study population. Evans et al. found
the prevalence of probable AD in age categories of 64–75 years, 75–
84 years and 85+ years to be 3.0%, 18.4% and 47.8%, respectively [28].
The prevalence of AD-related neuropathological findings among iNPH-
patients varies from 20% to 70% depending on the detection method
and cohort [9].
4.4. Perspectives into epidemiology
Notable geographical variation in the incidence of shunt-operated
iNPH patients was discovered, concentrating in Eastern Finland (Fig.
1). To exclude the effect of regional variation in the timeframe of re-
cruitment, only patients from the years with comparable data were
used in this analysis. The lower response rates in the Southern and
Northern Finland may have some confounding effect. Furthermore, re-
gional differences in the primary diagnostics and variable diagnostic
criteria for the surgery with the insidious nature of iNPH are potential
sources of error, yet hardly the sole cause of the detected variation. Het-
erogeneous epidemiological numbers reported on cohorts with differ-
ent population samples also support the hypothesis of potential
genetic variation despite considerable methodological differences [7–
10].
There is only a slight risk developing iNPH before senescence. Due to
limited attendance and potential diagnostic heterogeneity, the overall
epidemiological rates are surely underestimated. This is supported by
Jaraj et al. emphasizing that the prevalence of iNPH rapidly emerges
with age being up to 6% in population aged over 80 [9]. Thus, more tai-
lored epidemiological approaches with uniform inclusion criteria and
age-adjustment are required. For example, when evaluating siblings
and relative recurrence risk ratios, overall prevalence of iNPH gives ex-
tremely high values due to age distortion.
In addition, birth municipalities of familial and sporadic iNPH-pa-
tients were graphically illustrated. Similar east-bound trend remained
in birthplaces of both groups. However, no timeframe correction was
used which may skew the geographical incidence of iNPH families.
This requires further study, since biased timeframe, and regional varia-
tion in the diagnostics and response rates are potential cofounders.
Pastinen and colleagues investigated Finnish disease heritage muta-
tions resulting in regional clustering in both more common and rare
mutations [29]. Assumedly, this variation is due to sub-isolates andmul-
tiple bottlenecks formed, enriching such alleles regionally. The regional
accumulation discovered by us, supports the hypothesis of potential ge-
netic factors related with iNPH. The cases were examined in relation to
regional population aged over 60 years since symptomatic iNPH rarely
manifests at earlier age. This also reduces the bias caused by regional
differences in age composition yet the same trend persisted in analyses
based on total population values. Weighted age-adjusted regional anal-
ysis was unfortunately impossible due to the limited number of
patients.
4.5. APOE and other genetic aspects
In linewith Pyykkö et al., no significant difference was discovered in
the prevalence of APOE ε4 in iNPH patients compared with control pop-
ulation [30]. Based on our current findings, previous study and modest
regional variation found in APOE polymorphisms, it seems that ε4 allele
may be overexpressed in iNPHwith concomitantAD but does not have a
key role in the pathomechanism of solitary iNPH [30,31]. As only few
studies have yet investigated iNPH with genomic approach [17,18,32]
and frequent comorbid AD is well-documented [6,11], further studies
targeting the genes of amyloid cascade [33–35] and genome-wideapproaches are required. Shunted siblings are most likely to carry po-
tentialmutations playing the key role in iNPH and thus requiremore ac-
curate methodologies focusing on sequencing and functional genomics.
Recognizing more potential iNPH-pedigrees as well as more in-depth
genealogy searching for potential common bloodlines are also taken
into consideration.
4.6. Scientific significance and future perspectives
To conclude, the multiple iNPH-families discovered, offer a bench-
mark from which genetic studies can be considered. Analogically, our
approach with detected geographical variability andmultiple pedigrees
discovered has some similar characteristics compared to early studies of
Finnish familial intracranial aneurysms [36]. With respect to our pedi-
grees; both Mendelian and multifactorial inheritance ought to be con-
sidered. Rather late onset age of iNPH and incomplete penetrance of
potential alleles are also aspects taken into consideration. The first-de-
gree relatives offer an intriguing approach concerning both genomic
and preclinical longitudinal studies. Iseki et al. [8] performed a large-
scale neuroradiological study examining possible preclinical findings
of iNPH [8]. Authors suggested asymptomatic ventriculomegaly being
a potential preclinical sign of iNPH. Additionally, Liouta et al. introduced
daughters of two iNPH-sisters both, already in their forties, presented
with long-lasting urinary incontinence and ventricular enlargement
with empty sella [22]. Since pathophysiological knowledge of iNPH
has remained elusive during the past five decades, novel, unprejudiced
approaches are required both in the field of iNPH and
neurodegeneration.
5. Conclusions
1. There seems to be a familial subgroup of iNPH. Family history is
worth screening both in research and in clinical setting. The knowl-
edge of existing familial risk might hasten the otherwise late diagno-
sis on iNPH patients thus accelerating access to treatment.
2. More prevalent risk of dementia in familial group seems to be inde-
pendent from AD and APOE ε4 supporting iNPH to have potential
specific genetic pathways.
3. Our cohort and findings offer a novel opportunity to conduct genetic
studies and identify potential preclinical diagnostic and prognostic
factors for iNPH.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2016.06.052.
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